Related Experiment Video

Updated: Mar 15, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

A novel application of E1A in combination therapy with EGFR-TKI treatment in breast cancer

Chih-Ming Su1,2, Ting-Yu Chang3, Hui-Ping Hsu4

  • 1Division of General Surgery, Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei City, Taiwan, ROC.

Oncotarget
|September 4, 2016
PubMed

Insights

In breast cancer, high AXL levels reduce the effectiveness of EGFR tyrosine kinase inhibitors (EGFR-TKI). E1A protein suppresses AXL, enhancing EGFR-TKI efficacy and inhibiting tumor growth.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Epidermal growth factor receptor (EGFR) overexpression is linked to poor breast cancer outcomes.
  • Resistance to EGFR tyrosine kinase inhibitors (EGFR-TKI) is a significant clinical challenge.

Purpose of the Study:

  • To investigate the role of AXL in breast cancer progression and its impact on EGFR-TKI response.
  • To evaluate the therapeutic potential of E1A in overcoming resistance to EGFR-TKI.

Main Methods:

  • Correlation analysis of AXL expression with clinical outcomes in breast cancer patients.
  • In vitro studies using breast cancer cell lines to assess the effects of E1A on AXL expression and EGFR-TKI sensitivity.
  • Evaluation of tumor growth inhibition in response to combined E1A and EGFR-TKI treatment.

Main Results:

  • AXL expression was positively correlated with poor progression in breast cancer.
  • Suppression of AXL by E1A significantly enhanced sensitization to EGFR-TKI (gefitinib, erlotinib, lapatinib).
  • AXL overexpression diminished E1A-mediated EGFR-TKI sensitization and impaired tumor growth inhibition.

Conclusions:

  • Downregulation of AXL by E1A is a key mechanism for sensitizing breast cancer cells to EGFR-TKI.
  • Combination therapy involving AXL inhibitors or E1A gene therapy with EGFR-TKI represents a promising strategy for breast cancer treatment.
Keywords:
E1Acombination therapy

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.7K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
63
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K